Drug Overview
Xarelto (rivaroxaban; Bayer/Johnson & Johnson) is an oral anticoagulant indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) in the US, EU, and Japan. It inhibits free factor Xa, which interrupts the blood coagulation cascade, preventing both thrombin generation and thrombus formation. Xarelto inhibits prothrombinase activity and thrombin-induced platelet aggregation, thus reducing blood clots.
Xarelto also has a number of other indications, including acute coronary syndrome and stroke prevention in atrial fibrillation, as well as ongoing development for ischemic stroke and chronic heart failure.
Xarelto (rivaroxaban; Bayer/Johnson & Johnson) is an oral anticoagulant indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) in the US, EU, and Japan. It inhibits free factor Xa, which interrupts the blood coagulation cascade, preventing both thrombin generation and thrombus formation. Xarelto inhibits prothrombinase activity and thrombin-induced platelet aggregation, thus reducing blood clots.
Xarelto also has a number of other indications, including acute coronary syndrome and stroke prevention in atrial fibrillation, as well as ongoing development for ischemic stroke and chronic heart failure.
Table of Contents
Product ProfilesXarelto: Venous thromboembolism (VTE)
Xarelto: Chronic heart failure (CHF)
Xarelto: Stroke
Xarelto: Stroke prevention in atrial fibrillation (SPAF)
Xarelto: Acute coronary syndrome (ACS)
List of Figures
Figure 1: Xarelto for venous thromboembolism - SWOT analysis
Figure 2: Drug assessment summary of Xarelto for venous thromboembolism
Figure 3: Drug assessment summary of Xarelto for venous thromboembolism
Figure 4: Xarelto sales forecast for VTE in the US, Japan, and five major EU markets, by country, 2017-26
Figure 5: Xarelto for chronic heart failure - SWOT analysis
Figure 6: Drug assessment summary of Xarelto for chronic heart failure
Figure 7: Drug assessment summary of Xarelto for chronic heart failure
Figure 8: Xarelto sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26
Figure 9: Xarelto for ischemic stroke - SWOT analysis
Figure 10: Drug assessment summary of Xarelto in ischemic stroke
Figure 11: Drug assessment summary of Xarelto in ischemic stroke
Figure 12: Xarelto for stroke prevention in atrial fibrillation - SWOT analysis
Figure 13: Drug assessment summary of Xarelto for stroke prevention in atrial fibrillation
Figure 14: Drug assessment summary of Xarelto for stroke prevention in atrial fibrillation
Figure 15: Xarelto for acute coronary syndrome - SWOT analysis
Figure 16: Drug assessment summary for Xarelto in acute coronary syndrome
Figure 17: Drug assessment summary for Xarelto in acute coronary syndrome
List of Tables
Table 1: Xarelto drug profile
Table 2: Xarelto pivotal trial data in venous thromboembolism
Table 3: Xarelto late-phase trial data in venous thromboembolism
Table 4: Xarelto sales for VTE in the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 5: Xarelto drug profile
Table 6: Xarelto Phase III data in chronic heart failure
Table 7: Xarelto sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 8: Xarelto drug profile
Table 9: Xarelto Phase III trials in ischemic stroke
Table 10: Xarelto drug profile
Table 11: Xarelto pivotal trial data in stroke prevention in atrial fibrillation
Table 12: Xarelto late-phase trial data in stroke prevention in atrial fibrillation
Table 13: Xarelto ongoing late-phase clinical trial in stroke prevention in atrial fibrillation
Table 14: Xarelto drug profile
Table 15: Xarelto pivotal trial data in acute coronary syndrome
Table 16: Xarelto ongoing late-phase trial in acute coronary syndrome
